Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kashiv BioSciences Completes Enrollment in Phase III Trial of ADL018 Biosimilar to XOLAIR®
Details : ADL018 (omalizumab) a biosimilar candidate to Xolair is being evaluated in late-stage clinical trial studies for the treatment of chronic idiopathic urticaria.
Brand Name : ADL018
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 25, 2024
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Kashiv BioSciences Licenses Proposed Biosimilar to XOLAIR® (Omalizumab) from Amneal
Details : Through the license agreement, Amneal will commercialize ADL018 (omalizumab) in the US. It is being evaluated in late-stage clinical trial studies for the treatment of chronic idiopathic urticaria.
Brand Name : ADL018
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 01, 2024
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Alvotech will receive an exclusive license to commercialize AVT23 (also called ADL018), a proposed biosimilar to Xolair (omalizumab), which will be developed and manufactured by Kashiv.
Brand Name : AVT23
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 03, 2023
Lead Product(s) : Omalizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ADL018 (omalizumab) is a monoclonal antibody that inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils. It is being developed as a biosimilar candidate to XOLAIR® approved to treat chronic spontaneous ...
Brand Name : ADL018
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 02, 2023
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ADL018 (omalizumab) is a monoclonal antibody that inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils. It is being developed as a biosimilar candidate to XOLAIR® approved to treat chronic spontaneous ...
Brand Name : ADL018
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 05, 2023
Lead Product(s) : Omalizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegfilgrastim-pbbk
Therapeutic Area : Hematology
Study Phase : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
Details : Fylnetra (pegfilgrastim-pbbk) is a leukocyte growth factor which decreases the incidence of infection, indicated for patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of...
Brand Name : Fylnetra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 16, 2023
Lead Product(s) : Pegfilgrastim-pbbk
Therapeutic Area : Hematology
Highest Development Status : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Brand Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FYLNETRA® (pegfilgrastim-pbbk), used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence ...
Brand Name : Fylnetra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 21, 2022
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Brand Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
Details : FYLNETRA (Pegfilgrastim-pbbk) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.
Brand Name : Fylnetra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 31, 2022
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
Details : FYLNETRA (pegfilgrastim), is used to treat neutropenia (low neutrophils which are a type of white blood cells that fight infection) which is commonly experienced by patients undergoing chemotherapy.
Brand Name : Fylnetra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 27, 2022
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Filgrastim
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
Details : U.S. FDA approved biologics license application for RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen, to treat neutropenia which is commonly experienced by patients undergoing chemotherapy, acute myeloid leukemia and nonmyeloid malignancies.
Brand Name : Releuko
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 01, 2022
Lead Product(s) : Filgrastim
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?